ImmunityBio, Inc. IBRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $140.98M+352% | $113.29M+668% | $82.56M+1,026% | $56.6M+4,227% | $31.22M+10,238% | ||
| $933K+1,509% | $753K— | $371K— | $194K— | $58K— | ||
| $140.04M+349% | $112.54M+663% | $82.18M+1,021% | $56.41M+4,212% | $31.16M+10,219% | ||
| 99.3%-0.5pp | 99.3%-0.7pp | 99.6%-0.4pp | 99.7%-0.3pp | 99.8%-0.2pp | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $402.37M+16.8% | $369.32M+2.9% | $343.3M-7.9% | $341.97M-9.3% | $344.64M-6.2% | ||
| -$261.39M+16.6% | -$256.03M+25.6% | -$260.74M+27.6% | -$285.37M+20.7% | -$313.42M+9.4% | ||
| -185.4%+818pp | -226%+2,108pp | -315.8%+4,596pp | -504.2%+27,023pp | -1,003.8%+113,521pp | ||
| $51.88M+14.8% | $51.54M+30.0% | $50.74M-15.8% | $49.37M-41.5% | $45.19M-57.9% | ||
| -$595.7M— | -$98.17M— | —— | —— | —— | ||
| $7.83M+35.9% | $6.41M-19.7% | $5.29M-27.2% | $5.03M-8.8% | $5.76M+62.0% | ||
| -$854.5M-109% | -$351.61M+15.0% | -$348.69M+40.7% | -$367.14M+38.6% | -$409.42M+31.9% | ||
| $108K+146% | -$135K— | $0+100% | $35K+188% | -$234K-485% | ||
| -$854.53M-109% | -$351.4M+15.0% | -$348.62M+40.7% | -$367.09M+38.6% | -$409.1M+31.9% | ||
| -606.2%+704pp | -310.2%+2,495pp | -422.3%+7,595pp | -648.6%+45,043pp | -1,310.3%+197,684pp | ||
| -$0.85-46.6% | -$0.38+39.7% | -$0.41+55.4% | -$0.48+50.5% | -$0.58+46.8% | ||
| -$0.85-57.4% | -$0.38+35.6% | -$0.39+56.7% | -$0.44+54.6% | -$0.54+50.5% | ||
| 3.8B+28.7% | 3.6B+30.8% | 3.4B+32.0% | 3.1B+32.7% | 2.9B+38.8% | ||
| 3.8B+28.9% | 3.6B+31.1% | 3.4B+32.0% | 3.1B+32.4% | 2.9B+38.5% | ||
| —— | —— | —— | —— | —— | ||
| -$237.99M-26,840% | -$43.94M-201% | -$279K+99.2% | $890K+103% | $890K+102% | ||
| -$8.05M— | -$2.17M— | —— | —— | —— | ||
| $140.98M+352% | $113.29M+668% | $82.56M+1,026% | $56.6M+4,227% | $31.22M+10,238% | ||
| -$261.39M+16.6% | -$256.03M+25.6% | -$260.74M+27.6% | -$285.37M+20.7% | -$313.42M+9.4% | ||
| -$245.31M+17.3% | -$240.5M+26.4% | -$244.95M+28.4% | -$269.07M+21.3% | -$296.59M+9.4% | ||
| -$245.31M+17.3% | -$240.5M+26.4% | -$244.95M+28.4% | -$269.07M+21.3% | -$296.59M+9.4% | ||
| -174%+776pp | -212.3%+2,003pp | -296.7%+4,370pp | -475.4%+25,667pp | -949.9%+107,487pp | ||
| -$261.39M+16.6% | -$256.03M+25.6% | -$260.74M+27.6% | -$285.37M+20.7% | -$313.42M+9.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ImmunityBio, Inc.'s revenue?
- ImmunityBio, Inc. (IBRX) generated $141.0M in revenue over the trailing twelve months, up 351.5% year over year.
- Is ImmunityBio, Inc. profitable?
- ImmunityBio, Inc. is not currently profitable: it reported a net loss of $854.5M over the trailing twelve months, a -606.2% net margin.
- What are ImmunityBio, Inc.'s profit margins?
- Gross margin is 99.3% and operating margin is -185.4%, with a -606.2% net margin.
- What is ImmunityBio, Inc.'s earnings per share?
- ImmunityBio, Inc.'s diluted EPS over the trailing twelve months is $-0.85.
- Where does ImmunityBio, Inc.'s income statement data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
